Meet the Ribometrix team, where every individual is valued as part of a collaborative community sharing a common focus on advancing the field of modulating RNA biology to discover and develop transformative small-molecule drugs.
Company
Pioneering RNA-Targeted Small Molecule Therapeutics
Ribometrix is a preclinical biotechnology company leading efforts to deliver the full promise of small molecule therapeutics that directly target cellular RNAs. Our best-in-field drug discovery and development platform leverages proprietary, state-of-the art capabilities to target complex RNA structures, thereby modulating RNA function to correct disease-causing production of encoded proteins.
A Unique Drug Discovery Engine
Built on nearly a decade of proprietary advances, our platform combines the well-established power of small molecule drug discovery and development with best-in-field RNA-focused capabilities to realize the full potential of RNA targeting while avoiding the limitations of oligonucleotide-based modalities.
Our growing pipeline of preclinical programs leverages our game-changing RNA-adapted high throughput screening strategies, and our breakthrough ability to identify small molecules that correct disease-causing protein production solely through selective binding to the encoding mRNA. This core strategy is also complemented by the development of RNA-degrading add-ons for those cases where binding alone does not deliver modulation.
We believe our commitment to this new paradigm, driven by a unique platform that tailors the discovery strategy to each interventional opportunity, will deliver innovative new therapies to patients.
Our History
In June 2016, Drs. Katie Warner and Kevin Weeks leveraged state-of-the-art capabilities in RNA structure determination to found Ribometrix Inc. on a big idea: to realize the huge and well-recognized therapeutic potential of targeting disease-causing mRNAs by using small molecule drugs that bind to their complex folded structures, thereby bypass the limitations of oligonucleotide-based approaches.
Working in the heart of North Carolina’s vibrant Research Triangle Park, the company’s dedicated team has since tackled what is invariably one of the most arduous challenges in our industry: that of establishing a new therapeutic modality.
Through the careful and focused application of multidisciplinary expertise to enable a myriad of scientific, technical and strategic advances, we have successfully built a proprietary preclinical platform for RNA-targeting drug discovery and development. Having matured our capabilities and know-how over generations of wholly-owned and partnered programs, we continue to learn, grow and discover with a single goal in mind: to improve the lives of patients with unmet medical needs.
-
Our Mission
Leveraging RNA expertise to discover and develop transformative small-molecule drugs.
-
Our Vision
We are committed to improving the lives of patients and families by developing therapies through innovative science.
-
Our Values
Collaboration
We seek help when we need it and provide support when we can.
Integrity
We act with respect, sincerity, and transparency.
Innovation
We create with intent.
Empowerment
We are accountable for our actions and results.
Resilience
We conquer with persistence and adaptability.
Community
We foster camaraderie with shared purpose, values, and goals.
Ribometrix Leadership & Team
Join Our Team
We are a team of individuals driven by the spirit of innovation, collaboration, empowerment, and integrity who are committed to the goal of helping patients with our novel therapeutic approach.
If you are looking for an opportunity to pioneer new science, collaborate with great people, and ultimately help those in need, then Ribometrix may be the place for you.
Our Latest Updates
View All News-
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer
-
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024